New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - metronidazole 1000mg - suppository - 1000 mg - active: metronidazole 1000mg excipient: hard fat

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - metronidazole 500mg - suppository - 500 mg - active: metronidazole 500mg excipient: hard fat

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - metronidazole benzoate 64 mg/ml equivalent to 40 mg/ml metronidazole.;  ;   - oral suspension - 200 mg/5ml - active: metronidazole benzoate 64 mg/ml equivalent to 40 mg/ml metronidazole.     excipient: aluminium magnesium silicate citrus limon ethanol methyl hydroxybenzoate monobasic sodium phosphate dihydrate propyl hydroxybenzoate purified water sucrose liquid terpeneless orange oil

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - cimetidine - film-coated tablet - 400 milligram(s) - h2-receptor antagonists; cimetidine

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - filgrastim - injection, solution - 0.120mg/0.2ml - filgrastim 0.120mg/0.2ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - filgrastim - infusion, solution - 0.300 mg/0.5ml - filgrastim 0.300 mg/0.5ml

Singapore - English - HSA (Health Sciences Authority)

pfizer private limited - filgrastim - infusion, solution - 0.480 mg/0.5ml - filgrastim 0.480 mg/0.5ml

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: magnesium stearate; povidone; hypromellose; calcium hydrogen phosphate; maize starch; purified talc; macrogol 400 - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronide has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 400 mg - tablet, uncoated - excipient ingredients: hypromellose; magnesium stearate; purified talc; calcium hydrogen phosphate; macrogol 400; maize starch; povidone - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: povidone; macrogol 400; magnesium stearate; maize starch; calcium hydrogen phosphate; hypromellose - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. metronide has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.